FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2009617832> ?p ?o ?g. }

• W2009617832 endingPage "159" @default.
• W2009617832 startingPage "147" @default.
• W2009617832 abstract "Individuals of 60 years living in western countries generally have a mean life expectancy of 20 years at least. Therefore, when aged individuals present with AML, it is a necessity and a challenge to treat them as efficiently as possible. AML is mainly a disease of the elderly and accounts for more than 50% of its incidence among the general population. The treatment of older individuals with AML has remained difficult and its success is still limited. While in adults with AML of less than 60 years complete responses above 65% and survival rates of 35% are commonly obtained, progress in the treatment of elderly patients has been relatively small. As of today, approximately 50% of older patients may be induced into remission with chemotherapy, and, among these complete responders, only approximately 1 in 10 will survive free of leukaemia beyond 4 years after diagnosis. In fact, on one hand, these results represent the rationale and motivation for offering chemotherapy to the older population. On the other hand, they emphasize that major obstacles to better cure rates still exist. These stumbling blocks apparently relate to the restricted tolerance of older subjects to the exposure of chemotherapy and probably also a greater probability of unresponsiveness of the leukaemia to cytotoxic therapy. The haematopoietic growth factors still hold some promise and may improve outcome, but for the time being there is insufficient direct evidence to indicate a defined and established role. It is evident that new avenues should be pursued and trials specifically designed for elderly people with AML be conducted. These trials would need to address questions related to the choice of chemotherapeutic drugs (e.g. idarubicin versus mitoxantrone), their dose and schedule selection, the use of multidrug resistance modulators (to overcome intrinsic drug non-responsiveness), and the optimal clinical use of haematopoietic growth factors, including thrombopoietin. Since trials addressing specific questions regarding the development of treatment of elderly patients with AML have remained scarce, the initiation of these studies is sorely needed. One may hope that these clinical trials will provide some of the necessary answers and new clues, and will be useful to advance future therapy of elderly AML patients." @default.
• W2009617832 created "2016-06-24" @default.
• W2009617832 creator A5046775582 @default.
• W2009617832 date "1996-03-01" @default.
• W2009617832 modified "2023-10-03" @default.
• W2009617832 title "8 Treatment of the elderly patient with acute myeloid leukaemia" @default.
• W2009617832 cites W1481564836 @default.
• W2009617832 cites W1487506158 @default.
• W2009617832 cites W1757201400 @default.
• W2009617832 cites W1909698311 @default.
• W2009617832 cites W1979979370 @default.
• W2009617832 cites W1987287990 @default.
• W2009617832 cites W1990189905 @default.
• W2009617832 cites W2000275771 @default.
• W2009617832 cites W2000838340 @default.
• W2009617832 cites W2011564019 @default.
• W2009617832 cites W2028521588 @default.
• W2009617832 cites W2034215350 @default.
• W2009617832 cites W2042165433 @default.
• W2009617832 cites W2087075929 @default.
• W2009617832 cites W2152363012 @default.
• W2009617832 cites W2204518675 @default.
• W2009617832 cites W225277523 @default.
• W2009617832 cites W2274125263 @default.
• W2009617832 cites W2318674152 @default.
• W2009617832 cites W2339692928 @default.
• W2009617832 cites W2404892170 @default.
• W2009617832 cites W2415780251 @default.
• W2009617832 cites W2431965920 @default.
• W2009617832 cites W254720960 @default.
• W2009617832 cites W3112284273 @default.
• W2009617832 cites W3146129082 @default.
• W2009617832 cites W4236104993 @default.
• W2009617832 cites W4254786437 @default.
• W2009617832 doi "https://doi.org/10.1016/s0950-3536(96)80041-2" @default.
• W2009617832 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8730555" @default.
• W2009617832 hasPublicationYear "1996" @default.
• W2009617832 type Work @default.
• W2009617832 sameAs 2009617832 @default.
• W2009617832 citedByCount "31" @default.
• W2009617832 countsByYear W20096178322012 @default.
• W2009617832 countsByYear W20096178322013 @default.
• W2009617832 countsByYear W20096178322014 @default.
• W2009617832 countsByYear W20096178322015 @default.
• W2009617832 countsByYear W20096178322017 @default.
• W2009617832 countsByYear W20096178322023 @default.
• W2009617832 crossrefType "journal-article" @default.
• W2009617832 hasAuthorship W2009617832A5046775582 @default.
• W2009617832 hasBestOaLocation W20096178322 @default.
• W2009617832 hasConcept C120665830 @default.
• W2009617832 hasConcept C121332964 @default.
• W2009617832 hasConcept C126322002 @default.
• W2009617832 hasConcept C133925201 @default.
• W2009617832 hasConcept C177713679 @default.
• W2009617832 hasConcept C187212893 @default.
• W2009617832 hasConcept C2779134260 @default.
• W2009617832 hasConcept C2908647359 @default.
• W2009617832 hasConcept C2993296363 @default.
• W2009617832 hasConcept C61511704 @default.
• W2009617832 hasConcept C71924100 @default.
• W2009617832 hasConcept C99454951 @default.
• W2009617832 hasConceptScore W2009617832C120665830 @default.
• W2009617832 hasConceptScore W2009617832C121332964 @default.
• W2009617832 hasConceptScore W2009617832C126322002 @default.
• W2009617832 hasConceptScore W2009617832C133925201 @default.
• W2009617832 hasConceptScore W2009617832C177713679 @default.
• W2009617832 hasConceptScore W2009617832C187212893 @default.
• W2009617832 hasConceptScore W2009617832C2779134260 @default.
• W2009617832 hasConceptScore W2009617832C2908647359 @default.
• W2009617832 hasConceptScore W2009617832C2993296363 @default.
• W2009617832 hasConceptScore W2009617832C61511704 @default.
• W2009617832 hasConceptScore W2009617832C71924100 @default.
• W2009617832 hasConceptScore W2009617832C99454951 @default.
• W2009617832 hasIssue "1" @default.
• W2009617832 hasLocation W20096178321 @default.
• W2009617832 hasLocation W20096178322 @default.
• W2009617832 hasLocation W20096178323 @default.
• W2009617832 hasOpenAccess W2009617832 @default.
• W2009617832 hasPrimaryLocation W20096178321 @default.
• W2009617832 hasRelatedWork W1580426574 @default.
• W2009617832 hasRelatedWork W1977732319 @default.
• W2009617832 hasRelatedWork W1984877488 @default.
• W2009617832 hasRelatedWork W2089620537 @default.
• W2009617832 hasRelatedWork W2275480158 @default.
• W2009617832 hasRelatedWork W2323950372 @default.
• W2009617832 hasRelatedWork W2371214482 @default.
• W2009617832 hasRelatedWork W2407004706 @default.
• W2009617832 hasRelatedWork W2929987155 @default.
• W2009617832 hasRelatedWork W4238089809 @default.
• W2009617832 hasVolume "9" @default.
• W2009617832 isParatext "false" @default.
• W2009617832 isRetracted "false" @default.
• W2009617832 magId "2009617832" @default.
• W2009617832 workType "article" @default.